Community Investing Ideas

Global Weekly Picks

US$21.53
FV
70.8% undervalued intrinsic discount
2.7k
users have viewed this narrative
8users have liked this narrative
0users have commented on this narrative
49users have followed this narrative
US$1.2
FV
78.3% undervalued intrinsic discount
-50.39%
Revenue growth p.a.
3.7k
users have viewed this narrative
6users have liked this narrative
2users have commented on this narrative
19users have followed this narrative
US$512.4
26.8% overvalued intrinsic discount
unknown's Fair Value
Revenue
57.36% p.a.
Profit Margin
6.25%
Future PE
22.57x
Price in 2031
US$761.6
TSLA logo
Tesla

Tesla's Revenue to Soar 16% as Fair Value Hits 391.81 in Five Years

TESLA INC. NASDAQ: TSLA The Most Controversial Bet in Investing An Equity Narrative for Simply Wall St | February 2026 1.Read more

View narrative
0
users have viewed this narrative
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$391.81
5.1% overvalued intrinsic discount
Revenue
16.64% p.a.
Profit Margin
4%
Future PE
407.31x
Price in 2031
US$634.02
US$400
3.0% overvalued intrinsic discount
Revenue
11.54% p.a.
Profit Margin
5.31%
Future PE
290.91x
Price in 2030
US$642.48
US$190.45
26.5% undervalued intrinsic discount
0DTE's Fair Value
Revenue
10.9% p.a.
Profit Margin
12.82%
Future PE
12.13x
Price in 2031
US$288.4
PANW logo
Palo Alto Networks

Palo Alto Networks (PANW): Collateral Damage

PANW is down 22% over the past year and 10.9% in the last seven days alone. Most people are calling it a victim of AI disruption.Read more

View narrative
0
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$210
29.2% undervalued intrinsic discount
Pancham's Fair Value
Revenue
28.51% p.a.
Profit Margin
10.9%
Future PE
95.2x
Price in 2031
US$314.4
US$338.2
21.6% overvalued intrinsic discount
unknown's Fair Value
Revenue
6.27% p.a.
Profit Margin
19.59%
Future PE
46.75x
Price in 2031
US$499.58
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
603
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
US$100
91.3% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1